B Cell Clonality by PCR
Clinical System Name
Miscellaneous Test
Synonyms
B cell gene rearrangement
B-cell clonality analysis
B-cell gene rearrangement
IgH gene clonality
IgH gene rearrangement
IgK gene clonality
IgK gene rearrangement
Sample Requirements
Specimen: Whole Blood or Bone Marrow
Container(s): Lavender/EDTA
Preferred Vol: 10.0 mL Whole Blood or 2.0 mL Bone Marrow
Minimum Vol: 5.0 mL Whole Blood or 1.0 mL Bone Marrow
Note: While green top tubes are accepted for testing, there is documentation that heparin can interfere with some PCR assays.
Processing Instructions
Reject due to:
Spin: N
Aliquot: N
Temp: 2 - 4 C
Storage Location: CPA 3 Refrigerator, Send Outs rack.
Off-site Collection:
Stability
Specimen Type | Temperature | Time |
Whole Blood or Bone Marrow | Room Temp | 24 h |
Refrigerated | 4 d | |
Frozen | Unacceptable |
Availability
STAT | Performed | TAT |
N | T | 10 - 12 d |
Performing Laboratory
UW / Seattle Cancer Care Alliance
Hematopathology Laboratory
825 Eastlake Avenue E., G7-800
Seattle, WA 98109
Phone Number: (206) 288-7060
Intake Hours: Monday - Friday 08:00 - 18:30 PST
Department
Department: Send Outs
Phone Number: (206) 987-2563
CPT Codes
81261, 81264
Methodology
Method: Polymerase Chain Reaction (PCR)/Capillary Electrophoresis
Analytical Volume: 5.0 mL Whole Blood or 1.0 mL Bone Marrow
Limitations:
Send Out Instructions
Reference Test Name: | B Cell Clonality by PCR |
Reference Test Code: | BCELL |
Instructions: | Send Monday through Friday with the UW courier. |
Description
Monoclonal populations of B lymphocytes can be identified by testing for immunoglobulin heavy chain (IGH) and kappa light chain gene (IGK) rearrangement by the polymerase chain reaction. Our method, developed by the collaborative European BIOMED-2 Concerted Action study group, employs three multiplex primer sets, each recognizing one of three conserved “Framework Regions” (FR1, FR2, and FR3) of (IGH) variable gene segments (VH) and two multiplex primer sets targeting the kappa light chain locus (IGK). In a mixed population of B cells, the lymphoma cells must represent at least 1% of the total B cells in order to be detectable as clonal peaks in a polyclonal distribution of background peaks. Approximately 90% of B cell lymphomas produce a PCR product using the BIOMED-2 (IGH) and (IGK) primer sets. For patients whose lymphoma has been shown to have a detectable clonal B cell population, this assay can be a sensitive detector of minimal residual disease in post treatment, B cell depleted specimens.
Reference Ranges
Interpretive report provided.